Paes Leme Rodrigo Cuiabano, da Silva Raquel Bandeira
Laboratório Especial de Microbiologia Clínica (LEMC), Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil.
Department of Infectious Diseases, Centro Universitário de Volta Redonda, Volta Redonda, Brazil.
Front Microbiol. 2021 Jul 27;12:707629. doi: 10.3389/fmicb.2021.707629. eCollection 2021.
It has been demonstrated that some non-steroidal anti-inflammatory drugs (NSAIDs), like acetylsalicylic acid, diclofenac, and ibuprofen, have anti-biofilm activity in concentrations found in human pharmacokinetic studies, which could fuel an interest in repurposing these well tolerated drugs as adjunctive therapies for biofilm-related infections. Here we sought to review the currently available data on the anti-biofilm activity of NSAIDs and its relevance in a clinical context. We performed a systematic literature review to identify the most commonly tested NSAIDs drugs in the last 5 years, the bacterial species that have demonstrated to be responsive to their actions, and the emergence of resistance to these molecules. We found that most studies investigating NSAIDs' activity against biofilms were , and frequently tested non-clinical bacterial isolates, which may not adequately represent the bacterial populations that cause clinically-relevant biofilm-related infections. Furthermore, studies concerning NSAIDs and antibiotic resistance are scarce, with divergent outcomes. Although the potential to use NSAIDs to control biofilm-related infections seems to be an exciting avenue, there is a paucity of studies that tested these drugs using appropriate models of biofilm infections or in controlled human clinical trials to support their repurposing as anti-biofilm agents.
已证明某些非甾体抗炎药(NSAIDs),如乙酰水杨酸、双氯芬酸和布洛芬,在人体药代动力学研究中发现的浓度下具有抗生物膜活性,这可能会激发人们将这些耐受性良好的药物重新用作生物膜相关感染辅助治疗的兴趣。在此,我们试图回顾目前关于NSAIDs抗生物膜活性及其在临床背景下相关性的可用数据。我们进行了一项系统的文献综述,以确定过去5年中最常测试的NSAIDs药物、已证明对其作用有反应的细菌种类以及对这些分子的耐药性出现情况。我们发现,大多数研究NSAIDs对生物膜活性的研究使用的是非临床细菌分离株,可能无法充分代表引起临床相关生物膜相关感染的细菌群体。此外,关于NSAIDs与抗生素耐药性的研究很少,结果也不一致。尽管使用NSAIDs控制生物膜相关感染的潜力似乎是一个令人兴奋的途径,但很少有研究使用适当的生物膜感染模型或在对照人体临床试验中测试这些药物,以支持将其重新用作抗生物膜药物。